In an EORTC trial of temozolomide in the primary treatment of glioblastoma [1]MGMT methylation status was strongly prognostic for survival, and with a suggestion of a predictive effect [2] although this remains unproven within that trial. This evidence concerns the gene MGMT and glioblastoma.